Coming Soon

A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Age & Gender

12 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

James Coghill
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia, Lymphoma)
Transplant

IRB Number

23-2140

ClinicalTrials.gov

NCT06143891

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.